Published in Clinical Trials Week, September 5th, 2005
"Micafungin (FK463) is a new parenteral echinocandin" antifungal agent, according to oncologists in the United States, who conducted a "multicenter, phase I, open-label, sequential-group dose escalation study" to "assess the safety, tolerability, and pharmacokinetics of micafungin in neutropenic pediatric patients."
"A total of 77 patients stratified by age (2 to 12 and 13 to 17 years) received micafungin," noted N.L. Seibel and coauthors at the National Cancer Institute. "Therapy was initiated at 0.5 mg/kg per day and escalated to higher...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week